J&J’s first pso­ri­a­sis study ex­clu­sive to pa­tients of col­or opens door to new mar­ket­ing com­mu­ni­ca­tions

John­son & John­son’s first-ever clin­i­cal study in pso­ri­a­sis with pa­tients of col­or found its treat­ment Trem­fya works sim­i­lar­ly across di­verse pop­u­la­tions, but that’s not the on­ly re­sult it’s am­pli­fy­ing.

The phar­ma is eval­u­at­ing how the study can trans­late to meet­ing pa­tient and physi­cians’ un­met needs, in­clud­ing use of the 20,000 clin­i­cal im­ages col­lect­ed dur­ing the di­verse skin tone study. While plans are still in the works, J&J ex­pects to use the ro­bust data­base for gen­er­al ed­u­ca­tion as well as med­ical train­ing and physi­cian guid­ance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER